Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 14.

Journal Article

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Buettner, R., Wolf, J. and Kron, A. (2019). The national Network Genomic Medicine (nNGM). Model for innovative diagnostics and therapy of lung cancer within a public healthcare system. Pathologe, 40 (3). S. 276 - 281. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Castiglione, R., Alidousty, C., Wagener, S., Holz, B., Kron, A., Wolf, J., Merkelbach-Bruse, S., Reinhardt, C., Buettner, R. and Schultheis, A. M. (2018). Genetic MET alterations in non-small cell lung cancer: biologic differences and analogies. Virchows Arch., 473. S. S17 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M. and Wolf, J. (2018). Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. Oncol. Res. Treat., 41. S. 250 - 251. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Ihle, M. A., Merkelbach-Bruse, S., Michels, S., Nogova, L., Kron, A., Fischer, R., Serke, M., Ko, Y. -D., Gerigk, U., Schulte, W., Sebastian, M., Riedel, R., Holzem, A., Kambartel, K. -O., Buettner, R. and Wolf, J. (2017). Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

This list was generated on Sun Oct 17 02:56:53 2021 CEST.